Meeting
2021 ASCO Annual Meeting
Prevalence of hyperprogressive disease (HPD) mutations and correlations to immune-related biomarkers in a large pan-cancer Chinese cohort.
Authors
Shengli Yang
Department of Thoracic Surgery, Foshan First People's Hospital, Foshan, China
Shengli Yang , Xinyi Liu , Ting Bei , Mengli Huang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2649)
DOI
10.1200/JCO.2021.39.15_suppl.2649
Abstract #
2649
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI).
First Author: Camila Bragança Xavier
Poster
2021 ASCO Annual Meeting
Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.
First Author: Chul Kim
Poster
2020 ASCO Virtual Scientific Program
Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study.
First Author: Ethan Sokol
Poster
2018 ASCO Annual Meeting
Association of CDKN2A gene alteration with high expression of PD-L1.
First Author: Yan Zhang